News

Eli Lilly and Company and Akouos, Inc. announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of…
Read More...

Syncromune, Inc., a clinical stage biopharmaceutical company focused on the development of combination intratumoral immunotherapy announced that the Company has signed an exclusive…
Read More...

Kite, a Gilead Company announces that the European Commission (EC) has granted approval for the use of Yescarta (axicabtagene ciloleucel) for the treatment of adult patients with…
Read More...

ImaginAb, Inc., a global biotechnology company focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapies (RPT) products, is…
Read More...

Immune-Onc Therapeutics, Inc., a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, announced the dosing of the first…
Read More...

Gilead Sciences, Inc. and MacroGenics announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using…
Read More...

Oculis, SA. a global biopharmaceutical company developing treatments to save sight and improve eye care with breakthrough innovations and European Biotech Acquisition Corp, a special…
Read More...

Bavarian Nordic A/S announced that the Swiss Federal Office of Public Health and the Swiss Armed Forces have jointly ordered 100,000 doses of MVA-BN smallpox and monkeypox vaccine.…
Read More...

The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the granting of a conditional market authorization for Boehringer Ingelheim’s spesolimab…
Read More...

Novo Nordisk announced that the acquisition of Forma Therapeutics Holdings, Inc. (Forma), announced on 1 September 2022, has been completed. Following the expiration of Novo…
Read More...

Inceptor Bio, a cell therapy biotechnology company and Avectas, a cell engineering technology leader, announce their collaboration to improve the development and manufacturing of…
Read More...

Vita Therapeutics, a cell engineering company harnessing the power of genetics to develop novel cellular therapies to treat muscular dystrophies and cancers, announced the completion of…
Read More...

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck, known as MSD outside of the United States and Canada, announced that Merck…
Read More...

Xcell Biosciences Inc. (Xcellbio), an instrumentation company focused on cell and gene therapy applications, and aCGT Vector, a point-of-care cell and gene therapy-as-a-service (TaaS)…
Read More...

Pandemic Response Lab (PRL), a wholly owned subsidiary of Opentrons Labworks, Inc., announced two new three-target monkeypox tests, each developed and performed by its New York and…
Read More...

Tavros Therapeutics, Inc., a precision oncology platform company leading the new frontier of targeted therapies exploiting tumors’ genetic vulnerabilities, and Vividion Therapeutics,…
Read More...

WuXi Biologics and Toregem BioPharma announced that they have signed a Memorandum of Understanding (MOU) to form a strategic partnership in the development of TRG035, a monoclonal…
Read More...

Oncotelic Therapeutics, Inc through its wholly owned subsidiary Oncotelic Inc., a developer of treatments for rare and orphan indications, including Parkinson's Disease, PDAC, DIPG, and…
Read More...

SiSaf Ltd, an RNA delivery and therapeutics company, announces that it is initiating the U.S. FDA Regulatory process to obtain an Orphan Drug Designation for SIS-101-ADO, a siRNA…
Read More...

Pasithea Therapeutics Corp. a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, announced…
Read More...